Share-based Payment Arrangement, Expense of IN8BIO, INC. from 31 Mar 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
IN8BIO, INC. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2020 to 30 Sep 2025.
  • IN8BIO, INC. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $692,000, a 61% decline year-over-year.
  • IN8BIO, INC. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $3,303,000, a 39% decline year-over-year.
  • IN8BIO, INC. annual Share-based Payment Arrangement, Expense for 2024 was $5,000,000, a 14% increase from 2023.
  • IN8BIO, INC. annual Share-based Payment Arrangement, Expense for 2023 was $4,370,000, a 26% increase from 2022.
  • IN8BIO, INC. annual Share-based Payment Arrangement, Expense for 2022 was $3,467,000, a 58% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

IN8BIO, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $3,303,000 $692,000 -$1,072,000 -61% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $4,375,000 $955,000 -$216,000 -18% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $4,591,000 $831,000 -$409,000 -33% 01 Jan 2025 31 Mar 2025 10-Q 07 May 2025 2025 Q1
Q4 2024 $5,000,000 $825,000 -$427,000 -34% 01 Oct 2024 31 Dec 2024 10-K 13 Mar 2025 2024 FY
Q3 2024 $5,427,000 $1,764,000 +$524,000 +42% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $4,903,000 $1,171,000 +$152,000 +15% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $4,751,000 $1,240,000 +$381,000 +44% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025 2025 Q1
Q4 2023 $4,370,000 $1,252,000 +$330,000 +36% 01 Oct 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
Q3 2023 $4,040,000 $1,240,000 +$343,000 +38% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $3,697,000 $1,019,000 +$135,000 +15% 01 Apr 2023 30 Jun 2023 10-Q 12 Nov 2024 2024 Q3
Q1 2023 $3,562,000 $859,000 +$95,000 +12% 01 Jan 2023 31 Mar 2023 10-Q 12 Nov 2024 2024 Q3
Q4 2022 $3,467,000 $922,000 -$43,000 -4.5% 01 Oct 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
Q3 2022 $3,510,000 $897,000 +$420,000 +88% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $3,090,000 $884,000 +$492,000 +126% 01 Apr 2022 30 Jun 2022 10-Q 09 Nov 2023 2023 Q3
Q1 2022 $2,598,000 $764,000 +$403,000 +112% 01 Jan 2022 31 Mar 2022 10-Q 09 Nov 2023 2023 Q3
Q4 2021 $2,195,000 $965,000 +$662,000 +218% 01 Oct 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
Q3 2021 $1,533,000 $477,000 +$461,000 +2881% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $1,072,000 $392,000 +$372,000 +1860% 01 Apr 2021 30 Jun 2021 10-Q 10 Nov 2022 2022 Q3
Q1 2021 $700,000 $361,000 +$343,000 +1906% 01 Jan 2021 31 Mar 2021 10-Q 10 Nov 2022 2022 Q3
Q4 2020 $357,000 $303,000 01 Oct 2020 31 Dec 2020 10-K 17 Mar 2022 2021 FY
Q3 2020 $16,000 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $20,000 01 Apr 2020 30 Jun 2020 10-Q 10 Nov 2021 2021 Q3
Q1 2020 $18,000 01 Jan 2020 31 Mar 2020 10-Q 10 Nov 2021 2021 Q3

IN8BIO, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $5,000,000 +$630,000 +14% 01 Jan 2024 31 Dec 2024 10-K 13 Mar 2025 2024 FY
2023 $4,370,000 +$903,000 +26% 01 Jan 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
2022 $3,467,000 +$1,272,000 +58% 01 Jan 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
2021 $2,195,000 +$1,838,000 +515% 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
2020 $357,000 01 Jan 2020 31 Dec 2020 10-K 17 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.